Q&A with Melanoma March Fundraisers
10 March 2015
Adrienne and Georgia lost their mother Patricia in 2009. They are taking part in this year's Melanoma March for the second time and hope that with their fundraising they can help another family go through what they had to. Read about how they are rallying their team together and hope to raise as much as possible.
Why are you taking part in this years Melanoma March?
We are taking part in this year's Melanoma March as we sadly lost our mother in 2009 to this aggressive disease. Mum first found her mole on the inside of year leg 14 years prior to her death. Adrienne was in year 1 and Georgia was in year 11. At the time, both of us didn’t quite comprehend the seriousness of her illness, nor did we expect that it would return some years later. Mum went into remission and in 2008 we discovered that the cancer had returned and was growing in her abdomen. After major surgery to remove the cancer we received the news that the cancer had spread to many of Mum’s organs. Within a few months it eventually reached her brain and Mum lost her battle. Our Mum wasn’t lucky enough to have the option of the trials and programs that are offered to melanoma patients now. Upon her first diagnosis in 1994 there were very limited options and when the cancer returned, it was too late for her. We are marching to raise awareness of melanoma in the hope that people avoid the harsh sun, understand the dangers of UV exposure and maintain regular skin check ups – whether they have had melanoma in the past, are predisposed to it or just need to keep an eye out for changes. In addition to raised awareness it is so important to continue to raise funds in order to fund important trials. We can only dream about what could have been a better outcome for our mother. Yet we hope that other individuals can get access to such valuable treatment that our mum couldn’t. If our fundraising can help the lives of another family to not go through what we did, we will do all we can.
How are you fundraising for your team?
We have contacted all our friends and families and asked them to march with us or make a donation to our team. Friends are holding morning teas at work to rally marchers and raise funds. Adrienne is a school teacher and will be sharing her story and having a guest speaker at her school this week.
How many people are in your team?
At present we have around 20 marchers who will be walking with us. We hope this number will continue to grow this week!
What are some of your tips to get your friends and family to donate?
The power of social media is great. We have been posting daily reminders to donate and register and set up a facebook event which we regularly update. Sending out SMS reminders has also been effective. We find that thanking people publicly on Facebook everytime we receive a donation helps to remind people as well as provide positive encouragement for others! We have asked members of our team to repost the link to register and donate. The last year our team marched in Manly we raised over $2000. We are close to $1000 at the moment and are pushing for more donations to come through this week. It would be amazing to match or beat our last effort. We find that most people donate in the week leading up to the event.
Donate now. Every bit counts towards a cure.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.